{"nctId":"NCT04186845","briefTitle":"Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence","startDateStruct":{"date":"2020-05-04","type":"ACTUAL"},"conditions":["Prostate Cancer"],"count":391,"armGroups":[{"label":"Patients","type":"EXPERIMENTAL","interventionNames":["Drug: rhPSMA-7.3 (18F) Injection","Diagnostic Test: Positron emission tomography scan"]}],"interventions":[{"name":"rhPSMA-7.3 (18F) Injection","otherNames":["flotufolastat F18"]},{"name":"Positron emission tomography scan","otherNames":["PET scan"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Patient is male and aged \\>18 years old.\n2. History of localized adenocarcinoma of the prostate with prior curative intent treatment.\n3. An elevated PSA, clinically suspicious for biochemically recurrent disease:\n\n   * Following Radical Prostatectomy: PSA \\>0.2 ng/mL\n   * Following Radiotherapy: nadir +2 ng/mL.\n4. Potentially eligible for salvage therapy with curative intent.\n\nExclusion Criteria:\n\n1. Patients who are planned to have an x-ray contrast agent or other PET radiotracer \\<24 hours prior to the PET scan.\n2. Patients currently receiving Androgen Deprivation Therapy (ADT).","healthyVolunteers":false,"sex":"MALE","genderBased":true,"genderDescription":"Patients required to have suspected prostate cancer recurrence based on elevated PSA following prior therapy.","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Patient-level CDR and Region-level PPV of rhPSMA7.3 (18F) PET for BCR of Prostate Cancer Using Histopathology or Imaging as a SoT","description":"The CDR was defined as the percentage of all patients scanned who had at least one TP lesion (localized correspondence between rhPSMA-7.3 (18F) PET imaging and the reference standard) regardless of any coexisting FP findings. When determining the region-level PPV, all rhPSMA7.3 (18F) PET-positive regions (maximum of three per patient) were categorized as TP or FP regions using histopathology or imaging.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient-level CDR and Region-level PPV of rhPSMA-7.3 (18F) PET in Patients Who Had Negative Baseline Conventional Imaging","description":"Patient-level CDR was defined as the percentage of all patients scanned who had at least one TP lesion (localized correspondence between rhPSMA-7.3 (18F) PET imaging and the reference standard) regardless of any co-existing FP findings.\n\nRegion-Level PPV is defined as the regions which are true positive out of all regions with positive lesions.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient-level CDR and Region-level PPV of rhPSMA-7.3 (18F) PET for Recurrence in Those Patients With and Without Reference Standard Histopathology Available","description":"Patient-level CDR was defined as the percentage of all patients scanned who had at least one TP lesion (localized correspondence between rhPSMA-7.3 (18F) PET imaging and the reference standard) regardless of any co-existing FP findings.\n\nRegion-Level PPV is defined as the regions which are true positive out of all regions with positive lesions.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.4","spread":null},{"groupId":"OG001","value":"49.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.8","spread":null},{"groupId":"OG001","value":"45.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.9","spread":null},{"groupId":"OG001","value":"46.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.9","spread":null},{"groupId":"OG001","value":"42.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.0","spread":null},{"groupId":"OG001","value":"57.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.6","spread":null},{"groupId":"OG001","value":"49.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient-level CDR of rhPSMA-7.3 (18F) PET Stratified by PSA Level","description":"Patient-level CDR was defined as the percentage of all patients scanned who had at least one TP lesion (localized correspondence between rhPSMA-7.3 (18F) PET imaging and the reference standard) regardless of any co-existing FP findings. The last PSA level before the PET scan will be used to stratify the patients","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.5","spread":null},{"groupId":"OG001","value":"44.4","spread":null},{"groupId":"OG002","value":"65.1","spread":null},{"groupId":"OG003","value":"72.7","spread":null},{"groupId":"OG004","value":"61.1","spread":null},{"groupId":"OG005","value":"80.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.8","spread":null},{"groupId":"OG001","value":"41.3","spread":null},{"groupId":"OG002","value":"65.1","spread":null},{"groupId":"OG003","value":"70.5","spread":null},{"groupId":"OG004","value":"58.3","spread":null},{"groupId":"OG005","value":"83.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.7","spread":null},{"groupId":"OG001","value":"46.0","spread":null},{"groupId":"OG002","value":"62.8","spread":null},{"groupId":"OG003","value":"69.3","spread":null},{"groupId":"OG004","value":"58.3","spread":null},{"groupId":"OG005","value":"77.4","spread":null}]}]}]},{"type":"SECONDARY","title":"CDR of rhPSMA-7.3 (18F) PET in the Following Regions: Prostate/Prostate Bed, Pelvic Lymph Nodes, Other","description":"Patient-level CDR was defined as the percentage of all patients scanned who had at least one TP lesion (localized correspondence between rhPSMA-7.3 (18F) PET imaging and the reference standard) regardless of any co-existing FP findings. The analysis was performed for each region and for each of the blinded independent readers","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7","spread":null},{"groupId":"OG001","value":"21.6","spread":null},{"groupId":"OG002","value":"29.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.1","spread":null},{"groupId":"OG001","value":"19.4","spread":null},{"groupId":"OG002","value":"30.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.7","spread":null},{"groupId":"OG001","value":"22.4","spread":null},{"groupId":"OG002","value":"25.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients in Whom rhPSMA-7.3 (18F) PET Imaging Results Changed the Intended Patient Management (Major and Other Changes)","description":"This analysis used patients in the EAP who had documented patient management plans in the EDC before and after the rhPSMA-7.3 (18F) PET scan","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Reader Kappa Statistics of rhPSMA7.3 (18F) Scan Interpretation by the Blinded Independent Readers","description":"The Cohen's kappa statistic will be calculated to assess pairwise agreement between any 2 blinded independent readers","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":null}]}]}]},{"type":"SECONDARY","title":"Region-level PPV of rhPSMA-7.3 (18F) PET Stratified by PSA Level","description":"Region-Level PPV is defined as the regions which are true positive out of all regions with positive lesions.. The last PSA level before the rhPSMA-7.3 (18F) PET scan was used to stratify patients.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.1","spread":null},{"groupId":"OG001","value":"37.1","spread":null},{"groupId":"OG002","value":"45.6","spread":null},{"groupId":"OG003","value":"57.7","spread":null},{"groupId":"OG004","value":"57.9","spread":null},{"groupId":"OG005","value":"59.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.8","spread":null},{"groupId":"OG001","value":"51.8","spread":null},{"groupId":"OG002","value":"57.4","spread":null},{"groupId":"OG003","value":"65.0","spread":null},{"groupId":"OG004","value":"71.7","spread":null},{"groupId":"OG005","value":"62.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.5","spread":null},{"groupId":"OG001","value":"45.1","spread":null},{"groupId":"OG002","value":"52.5","spread":null},{"groupId":"OG003","value":"64.9","spread":null},{"groupId":"OG004","value":"58.7","spread":null},{"groupId":"OG005","value":"60.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Region-level PPV of rhPSMA-7.3 (18F) PET for Recurrence in Those Patients With and Without Reference Standard Histopathology Available","description":"Region-Level PPV is defined as the regions which are true positive out of all regions with positive lesions. The data are analysed by whether the patients have had histopathology as reference standard.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.9","spread":null},{"groupId":"OG001","value":"42.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.0","spread":null},{"groupId":"OG001","value":"57.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.6","spread":null},{"groupId":"OG001","value":"49.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":391},"commonTop":["Hypertension","Diarrhea","Injection site reaction","Headache","Flushing"]}}}